Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 4Completed 4Withdrawn 3Unknown 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia 7Myelodysplastic Syndromes 5Multiple Myeloma 5Neoplasms, Plasma Cell 4Leukemia, Myelomonocytic, Chronic 4Anemia, Refractory, with Excess of Blasts 4Leukemia, Myeloid, Acute 3Anemia, Refractory 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1

Interventions

Melphalan 16Cyclophosphamide 14Dexamethasone 13fludarabine phosphate 12Filgrastim 11Antilymphocyte Serum 11fludarabine 8Radiotherapy 8Mycophenolic Acid 8Cyclosporine 8Busulfan 8Whole-Body Irradiation 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Methylprednisolone 6Lenalidomide 6Bortezomib 6pomalidomide 5Rituximab 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Flow Cytometry 4Etoposide 4Arsenic Trioxide 4liposomal doxorubicin 3Thalidomide 3Surveys and Questionnaires 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Plasma Cell × Arsenic Trioxide × Clear all
NCT00017433 2020-10-06

Arsenic Trioxide in Treating Patients With Multiple Myeloma

CTI BioPharma

Phase 2 Terminated
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00017069 2020-10-05

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

CTI BioPharma

Phase 2 Terminated
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00006220 2013-02-06

Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy

Washington University School of Medicine

Phase 1/2 Terminated
5 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00227682 2012-05-28

Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

OHSU Knight Cancer Institute

Phase 2 Terminated
2 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡